Procaterol 

Procaterol is an oral selective β2 adrenergic receptor agonist. Procaterol inhibits eosinophil migration and the release of eosinophil chemotactic factor from BEAS-2B cells through a cyclic AMP-dependent mechanism. Procaterol has a large dose difference existing between the bronchodilator effect and the anabolic effect in rat, can be used for asthma research in athletes^[1].

Procaterol (10-1000 ng/mL, 12, 24, 48 h, BEAS-2B) directly inhibits eosinophil migration and the release of eosinophil chemotactic factor from BEAS-2B cells through a cyclic AMP-dependent mechanism^[3].
Procaterol (10-1000 ng/mL, 12, 24, 48 h, BEAS-2B) Dose-dependent inhibition of RANTES release in response to IL-1b and TNF-a in BEAS-2B cell monolayers, and enhancement of GM-CSF mRNA expression in response to IL-1b^[3].
Procaterol (0.1 μM, 72 h, Human tracheal surface epithelial cells) reduce rhinovirus titers and RNA, cytokine concentrations, susceptibility to rhinovirus infection, and the expression of intercellular adhesion molecule-1 (ICAM-1), the receptor for type 14 rhinovirus, and the number of acidic endosomes in the cells from which rhinovirus RNA enters into the cytoplasm^[4].
Procaterol (10 nM, one time, Lung epithelial cells) increased ciliary bend amplitude (CBA) and ciliary beating frequency (CBF) in a dose dependent manner via cAMP^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Procaterol (0.03-1 mg/kg, inhalation 3 times a day, 14 days) has no significant changes in weight or body weight gain in rat gastrocnemius muscle^[1].
Procaterol (1 mg/kg, inhalation 3 times a day, 14 days) significantly increases weight of the levator ani muscle with anabolic effects^[1].
Procaterol (1 mg/kg, inhalation 3 times a day, 14 days) increases ventral prostate weight is associated with drug stimulation of b2 adrenergic receptors in tissues^[1].
Procaterol (0.03-1 mg/kg, inhalation 3 times a day, 14 days) different dose between bronchodilator and anabolic effects >30-fold, <100-fold^[1].
Procaterol (0.1, 1, 10 mg/kg, orally, before ovalbumin (HY-W250978) (OVA) inhalation) inhaler does not enhance airway hyperresponsiveness, airway wall inflammation, or airway wall thickening, and decreases eosinophil number^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

290.36

C₁₆H₂₂N₂O₃

72332-33-3

O[C@@H](C(C=C1)=C(C=CC2=O)C(N2)=C1O)[C@@H](CC)NC(C)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ikezono K, et al. Bronchodilating effect and anabolic effect of inhaled procaterol. Int J Sports Med. 2008 Nov;29(11):888-94.  [Content Brief]

  [2]. Tashimo H, et al. Effect of procaterol, a beta(2) selective adrenergic receptor agonist, on airway inflammation and hyperresponsiveness. Allergol Int. 2007 Sep;56(3):241-7.  [Content Brief]

  [3]. Koyama S, et al. Procaterol inhibits IL-1beta- and TNF-alpha-mediated epithelial cell eosinophil chemotactic activity. Eur Respir J. 1999 Oct;14(4):767-75.  [Content Brief]

  [4]. Yamaya M, et al. Procaterol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Eur J Pharmacol. 2011 Jan 10;650(1):431-44.  [Content Brief]

  [5]. Komatani-Tamiya N, et al. Procaterol-stimulated increases in ciliary bend amplitude and ciliary beat frequency in mouse bronchioles. Cell Physiol Biochem. 2012;29(3-4):511-22.  [Content Brief]